
Management of Adverse Effects Associated With Novel Therapies
2022-06-09
0:00
13:25
Management of relapsed/refractory LBCLs remains a substantial and persistent clinical challenge, including optimal treatment sequencing, therapy evaluation and patient selection, and toxicity management.
Fler avsnitt från "A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy"
Missa inte ett avsnitt av “A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy” och prenumerera på det i GetPodcast-appen.